AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.

The approval was granted by the Food and Drug Administration based on results from the DESTINY-Breast06 phase 3 trial, which were presented at the 2024 American Society of Clinical Oncology ...